Objective To define a rational, cost-effective, simple approach to managing most patients
with papillary thyroid cancer (PTC) who are at low-risk of either cause-specific mortality or …

Papillary thyroid carcinoma (PTC) accounts for over 90% of all thyroid cancers in Japan. The
majority of patients with PTC are categorized into a low-risk group according to the recent …

Purpose: To evaluate the role of radioiodine and external radiotherapy treatment in papillary
thyroid carcinoma (PTC). Methods and Materials: This is a retrospective study of 842 …

Background: The American Thyroid Association guidelines recommend the routine use of
radioactive iodine for remnant ablation (RRA) in all T3 or greater primary tumors, and …

It is uncertain whether more extensive primary surgery and increasing use of radioiodine
remnant ablation (RRA) for papillary thyroid carcinoma (PTC) have resulted in improved …

Background: Detection of recurrent/persistent thyroid cancer has improved significantly in
the past decade. Disease is detected earlier in recently treated patients and localized in …

Background Our original system for risk group classification for predicting cause-specific
death from papillary thyroid carcinoma (PTC) defined patients with distant metastasis and …

Abstract 2,512 consecutive patients with papillary thyroid carcinoma (PTC) were managed
during 1940 through 2000 at the Mayo Clinic. During that period, there were two significant …

To identify indications for external radiotherapy (EXT) and radioactive iodine (RAI) in
papillary thyroid carcinoma (PTC), we conducted a retrospective study of local and regional …

The use of radioactive iodine (RAI) ablation in patients with intermediate-risk papillary
thyroid carcinoma (PTC) who show microscopic extrathyroidal extension (ETE), regional …